Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
30 active trials across 6 therapeutic areas
30
Active Trials
16
Phase 1
12
Phase 2
5
Phase 3
6
Therapeutic Areas
Portfolio Concentration: 77% of active trials in Oncology
Oncology
23 active / 27 total
Breast Cancer
6 active
3 Ph3
6 total since 2015
Solid Tumor (Advanced)
4 active
5 total since 2015
Multiple Myeloma
2 active
2 total since 2015
NSCLC
2 active
2 total since 2015
Colorectal Cancer
2 active
2 total since 2015
Cholangiocarcinoma
1 active
1 total since 2015
HER2+ Breast Cancer
1 active
1 Ph3
1 total since 2015
Hematologic Malignancies
1 active
1 total since 2015
Esophageal Cancer
1 active
1 total since 2015
Pancreatic Cancer
1 active
1 total since 2015
Lung Cancer (General)
1 active
1 total since 2015
CML
1 active
1 total since 2015
Sarcoma
0 active
2 total since 2015
Non-Hodgkin Lymphoma
0 active
1 total since 2015
Immunology
3 active / 7 total
Urology
2 active / 2 total
Respiratory
1 active / 2 total
Metabolic
1 active / 1 total
Rare Disease
1 active / 1 total
Click an indication to see competitive landscape (all sponsors in that indication).
Data: ClinicalTrials.gov (2015+)